Enhancing Cancer Treatment Decisions with Ultrasensitive MRD Testing

Quest, Diagnostics, MRD, minimal residual testing, precision, biomarker

Dr. Thomas Slavin breaks down how ultrasensitive MRD testing supports better cancer treatment decisions and enables earlier, more personalized interventions.

Jul 7^th • 19 mins listen

Tumor-Agnostic Therapies and the Future of HER2 in Oncology

diagnostic, precision oncology, tumor agnostic, breast cancer, gastric cancer, biomarker

What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.

Jun 8^th • 20 mins listen

Rethinking How We Track and Treat Cancer

diagnostic, genomics, breast cancer, antibody drug conjugate, ADC, breast cancer, lung cancer, biomarker

HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics.

Jul 13^th • 19 mins listen

Redefining Ovarian Cancer Care with Biomarkers

diagnostic, ovarian cancer, biomarker, tumor biology

Exploring ovarian cancer, biomarkers HRD & RB1, and how Labcorp innovations are advancing precision oncology.

Sep 7^th • 14 mins listen

ctDNA Breakthroughs in Mesothelioma Care

diagnostic, immunotherapy, imaging

Exploring immunotherapy and ctDNA innovation in mesothelioma, where molecular monitoring may redefine early cancer detection and treatment.

Nov 3^rd • 15 mins listen